PMID- 34231458
OWN - NLM
STAT- MEDLINE
DCOM- 20211208
LR  - 20211214
IS  - 1001-9294 (Print)
IS  - 1001-9294 (Linking)
VI  - 36
IP  - 2
DP  - 2021 Jun 30
TI  - Methylenetetrahydrofolate Reductase Gene Polymorphism C677T is Associated with 
      Increased Risk of Coronary Heart Disease in Chinese Type 2 Diabetic Patients.
PG  - 103-109
LID - 10.24920/003792 [doi]
AB  - Objective Chronic cardiovascular diseases induced by long-term poor blood glucose 
      control are the main cause of death in patients with type 2 diabetes mellitus 
      (T2DM). Previous researches report that methylenetetrahydrofolate reductase gene 
      (MTHFR) polymorphisms might influence the occurrence of coronary heart disease 
      (CHD) in T2DM patients. The purpose of this study was to evaluate whether MTHFR 
      C677T and A1298C mutations are associated with the risk of CHD in T2DM patients. 
      Methods A total of 197 subjects with T2DM were studied, of which 95 patients with 
      CHD. The genotypes of MTHFR C677T and A1298C were analyzed by using dideoxy 
      chain-termination method, and compared between patients with CHD and those 
      without CHD. Results We found that the frequency of the 677T allele was 
      significantly higher in T2DM patients with CHD than those without CHD (P=0.011). 
      However, there was no significant difference in any of the examined haplotypes 
      between T2DM patients with and without CHD. Furthermore, the 677T allele was 
      associated with a higher risk of CHD development in diabetic patients with lower 
      homocysteine (Hcy) levels (</=15 mumol/L) (P=0.006), while no effect of MTHFR gene 
      polymorphism on the incidence of CHD was found in patients with higher Hcy levels 
      (>15 mumol/L) (P=0.491). Conclusion The MTHFR C677T gene polymorphism is 
      associated with the risk of CHD of diabetic patients and could be used as an 
      effective marker for CHD in Chinese diabetic populations with normal Hcy levels.
FAU - Wu, Kun Rong
AU  - Wu KR
AD  - Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First 
      Medical University, Jinan 250014, China.
FAU - Zhang, Shu Fang
AU  - Zhang SF
AD  - School of Pharmaceutical Sciences, Shandong First Medical University (Shandong 
      Academy of Medical Sciences) Tai'an 271000, Shandong, China.
FAU - Guan, Zi Wan
AU  - Guan ZW
AD  - Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First 
      Medical University, Jinan 250014, China.
FAU - Li, Xiao Li
AU  - Li XL
AD  - School of Pharmaceutical Sciences, Shandong First Medical University (Shandong 
      Academy of Medical Sciences) Tai'an 271000, Shandong, China.
FAU - Li, Rui
AU  - Li R
AD  - Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First 
      Medical University, Jinan 250014, China.
FAU - Yin, Ying
AU  - Yin Y
AD  - School of Pharmaceutical Sciences, Shandong First Medical University (Shandong 
      Academy of Medical Sciences) Tai'an 271000, Shandong, China.
FAU - Li, Yan
AU  - Li Y
AD  - Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First 
      Medical University, Jinan 250014, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin Med Sci J
JT  - Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
JID - 9112559
RN  - EC 1.5.1.20 (Methylenetetrahydrofolate Reductase (NADPH2))
SB  - IM
MH  - China/epidemiology
MH  - *Coronary Disease/epidemiology/genetics
MH  - *Diabetes Mellitus, Type 2/genetics
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Methylenetetrahydrofolate Reductase (NADPH2)/genetics
MH  - Polymorphism, Genetic
MH  - Risk Factors
EDAT- 2021/07/08 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/07/07 08:44
PHST- 2021/07/07 08:44 [entrez]
PHST- 2021/07/08 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
AID - 1625625999583-1260888014 [pii]
AID - 10.24920/003792 [doi]
PST - ppublish
SO  - Chin Med Sci J. 2021 Jun 30;36(2):103-109. doi: 10.24920/003792.